Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Poxel
  6. Summary
    POXEL   FR0012432516

POXEL

(POXEL)
  Report
Real-time Quote. Real-time Euronext Paris - 06/11 11:39:02 am
7 EUR   +2.19%
06/01POXEL  : Corporate Presentation
PU
05/21Today on Wall Street: Poor manufacturing data boosts indexes
05/14POXEL  : Corporate Profile May 2021
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
6.96(c) 7.08(c) 6.78(c) 6.85(c) 7(c) Last
35 343 44 507 179 675 57 699 64 179 Volume
+0.51% +1.72% -4.24% +1.03% +2.19% Change
More quotes
Financials
Sales 2021 26,8 M 32,5 M 32,5 M
Net income 2021 -32,2 M -39,0 M -39,0 M
Net cash position 2021 36,4 M 44,1 M 44,1 M
P/E ratio 2021 -5,91x
Yield 2021 -
Sales 2022 21,5 M 26,0 M 26,0 M
Net income 2022 -32,2 M -39,0 M -39,0 M
Net Debt 2022 11,9 M 14,4 M 14,4 M
P/E ratio 2022 -6,11x
Yield 2022 -
Capitalization 200 M 242 M 242 M
EV / Sales 2021 6,10x
EV / Sales 2022 9,88x
Nbr of Employees 50
Free-Float 80,1%
More Financials
Company
Poxel is a biopharmaceutical company that specializes in the development of medicines for the treatment of metabolic diseases, primarily type II diabetes. At the end of 2020, the group had a portfolio of 4 products in clinical development, including 1 in Phase III (Imeglimin for the treatment of type II diabetes and its associated pathologies) and 3 in phase II (PXL770, PXL065 and PXL007 for the treatment of... 
More about the company
Ratings of Poxel
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about POXEL
06/01POXEL  : Corporate Presentation
PU
05/21Today on Wall Street: Poor manufacturing data boosts indexes
05/14POXEL  : Corporate Profile May 2021
PU
05/05POXEL  : Corporate Presentation
PU
05/03POXEL  : Corporate Presentation
PU
04/22GLOBAL MARKETS LIVE : Chevron, Toyota, Sony...
04/21POXEL  : 1st quarter earnings
CO
03/31POXEL  : Corporate Profile March 2021
PU
03/25POXEL  : Announces availability of its 2020 Universal Registration Document
PU
03/25POXEL  : Document d'Enregistrement Universel 2020
PU
03/25POXEL  : Full Year 2020 Financial and Corporate Update
PU
03/25POXEL  : Report
CO
03/24POXEL  : Full Year 2020 Financial and Corporate Presentation - English
PU
03/24POXEL  : Corporate Presentation - English
PU
03/24POXEL  : Reports Financial Results for Full Year 2020 and Provides Corporate Upd..
BU
More news
News in other languages on POXEL
05/28POXEL  : Degroof Petercam rehausse son objectif
05/26POXEL  : Document d'Enregistrement Universel 2020
05/21STOCK MARKET PARIS : Toutes les nouvelles sont bonnes à prendre
05/21EN DIRECT DES MARCHES  : Total, Saint-Gobain, Vallourec, Derichebourg, Neoen, Ri..
05/11POXEL  : annonce sa participation au 64ème Congrès annuel de la Société Japonais..
More news
Chart POXEL
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 15,50 €
Last Close Price 7,00 €
Spread / Highest target 200%
Spread / Average Target 121%
Spread / Lowest Target 42,9%
EPS Revisions
Managers and Directors
NameTitle
Thomas Kuhn Chief Executive Officer & Director
Anne Renevot Chief Financial Officer & Executive Vice President
Pierre Legault Chairman
Sophie Hallakou-Bozec Senior Vice President-Research & Development
Takashi Kaneko Senior Vice President-Medical
Sector and Competitors
1st jan.Capitalization (M$)
POXEL10.06%242
GILEAD SCIENCES, INC.18.04%86 250
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE192.63%57 615
REGENERON PHARMACEUTICALS8.78%54 424
VERTEX PHARMACEUTICALS-18.33%49 966